LOS ANGELES, Aug. 10, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ARS Pharmaceuticals, Inc., (“ARS” or the "Company") (NASDAQ: SPRY) investors of a class action on behalf of investors that bought securities between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”). ARS investors have until October 5, 2026 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/ars-pharmaceuticals-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
ARS Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for severe allergic reactions. ARS Pharmaceuticals is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
The ARS Pharmaceuticals class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants knew or recklessly disregarded potential timeline issues with CVS Caremark’s formulary addition and coverage decision related to neffy; (ii) the guidance ARS Pharmaceuticals provided to investors related to the timeline for expansion of insurance coverage for neffy with CVS Caremark may be significantly shifted, impacting commercialization efforts; and (iii) the expanded insurance coverage may not be available by the July 1 deadline, thus, ARS Pharmaceuticals would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.
On June 24, 2026, after the market closed, ARS Pharmaceuticals published a press release allegedly announcing that ARS Pharmaceuticals did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS Pharmaceuticals did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS Pharmaceuticals allegedly also stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, the price of ARS Pharmaceuticals stock declined nearly 24%, according to the complaint.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
